Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients

Abstract

The objective of the study was to analyse the prevalence and clinical significance of hypocomplementemia in a large series of patients diagnosed either with systemic lupus erythematosus (SLE) or with primary antiphospholipid syndrome (APS) and its association with the main clinical, hematological and immunological features of these diseases. Between 1992 and 2003, complement determinations (C3 and C4 levels, CH50 activity) were performed in 597 consecutive patients diagnosed with SLE (530 women and 67 men, mean age 32.6 years) and 70 with primary APS (57 women and 13 men, mean age 38.7) visited in our department. Complement determinations are routinely made at the first visit of patients and yearly during the follow-up. SLE and primary APS were diagnosed according to current classification criteria. Hypocomplementemia was detected in 371 (62%) of SLE patients. Compared with patients with normal complement values, those with hypocomplementemia showed a higher prevalence of female gender (P < 0.001), fever (P = 0.021), nephropathy (P < 0.001), cutaneous vasculitis (P = 0.023), positive anti-dsDNA antibodies (P = 0.012) and cryoglobulinemia (P < 0.001). In addition, patients with hypocomplementemia showed a higher prevalence of APS-related features such as hemolytic anemia (P = 0.001) and antiphospholipid antibodies (P < 0.001). Hypocomplementemia was prospectively related to accumulated hospitalization in SLE patients but not with the accumulated number of lupus flares or with the survival after follow-up of five years. In contrast, 33 (47%) patients with primary APS presented low complement values, which were associated with a higher prevalence of livedo reticularis (P = 0.022), thrombocytopenia (P = 0.004), lupus anticoagulant (P = 0.013), positive IgM-aCL (P = 0.039), positive ANA (P = 0.002) and anti-dsDNA (P = 0.046). The diagnostic value of hypocomplementemia in patients with SLE is based on the association with disease activity, immune-complex mediated manifestations (glomerulonephritis, cryoglobulinemia) and APS-related features (livedo reticularis, hemolytic anemia and aPL). Hypocomplementemia was found in nearly half of patients with primary APS, and was associated with some APS features (livedo reticularis, thrombocytopenia, aPL) but also with SLE-related immunological markers (ANA and anti-dsDNA), identifying a subset of patients with primary APS with a higher risk of evolving to SLE. These results clearly support the routine determination of complement factors in the clinical follow-up of patients with SLE and primary APS.

Keywords

complement cryoglobulinemia hypocomplementemia primary APS SLE

Get full access to this article

View all access options for this article.

References

Walport MJ. Complement. First of two parts . N Engl J Med 2001; 344: 1058-1066 .

Molina H. Update on complement in the pathogenesis of systemic lupus erythematosus . Curr Opin Rheumatol 2002; 14: 492-497 .

Wallace DJ , Hahn BH , Klippel JH. Lupus nephritis. In Wallace DJ , Hahn BH eds. Dubois’s lupus erythematosus, 5th edn. Pennsylvania: Williams and Wilkins , 1997: 1053-1065.

Kobayashi N , Yamada H , Kishida T et al. Hypocomplementemia correlates with intrauterine growth retardation in systemic lupus erythematosus . Am J Reprod Immunol 1999; 42: 153-159 .

Lev S , Shoenfeld Y. Cardiac valvulopathy in the antiphospholipid syndrome . Clin Rev Allergy Immunol 2002; 23: 341-348 .

Cortes-Hernandez J , Ordi-Ros J , Paredes F , Casellas M , Castillo F , Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies . Rheumatology (Oxford) 2002; 41: 643-650 .

Munakata Y , Saito T , Matsuda K , Seino J , Shibata S , Sasaki T. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis . Thromb Haemost 2000; 83: 728-731 .

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .

Wilson WA , Gharavi AE , Koike T , et al. International consensus statement on preliminary classification criteria for definite anti-phospholipid syndrome . Arthritis Rheum 1999; 42: 1309-1311 .

10.

Cervera R , Khamashta MA , Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus . Medicine (Baltimore) 1993; 72: 113-124 .

11.

Cervera R , Piette JC , Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients . Arthritis Rheum 2002; 46: 1019-1027 .

12.

Cervera R , Khamashta MA , Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients . Medicine (Baltimore) 1999; 78: 167-175 .

13.

Lachmann PJ , Hobart MJ. Complement technology. In Weir DM ed. Handbook of experimental immunology, Vol. 1, Oxford, UK: Blackwell Scientific Publications , 1978: 12-13.

14.

Yamamoto S , Kubotsu K , Kida M. Automated homogeneous liposome-based assay system for total complement activity . Clin Chem 1995; 41: 586-590 .

15.

Trejo O , Ramos-Casals M , Garcia-Carrasco M et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center . Medicine (Baltimore) 2001; 80: 252-262 .

16.

Buyon JP , Tamerius J , Belmont HM , Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement . Arthritis Rheum 1992; 35: 1028-1037 .

17.

Porcel JM , Ordi J , Castro-Salomo A et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares . Clin Immunol Immunopathol 1995; 74: 283-288 .

18.

Manzi S , Rairie JE , Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity . Arthritis Rheum 1996; 39: 1178-1188 .

19.

Vlachoyiannopoulos PG , Karassa FB , Karakostas KX , Drosos AA , Moutsopoulos HM. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients . Lupus 1993; 2: 303-312 .

20.

Moss KE , Ioannou Y , Sultan SM , Haq I , Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades . Ann Rheum Dis 2002; 61: 409-413 .

21.

Ho A , Barr SG , Magder LS , Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus . Arthritis Rheum 2001; 44: 2350-2357 .

22.

Hebert LA , Cosio FG , Neff JC. Diagnostic significance of hypocomplementemia . Kidney Int 1991; 39: 811-821 .

23.

Petri M , Watson R , Winkelstein JA , McLean RH. Clinical expression of systemic lupus erythematosus in patients with C4A deficiency . Medicine (Baltimore) 1993; 72: 236-244 .

24.

Vaughan JH , Bayles TB , Savour CB. The response of serum gammaglobulin level and complement titer to adrenocorticotrophic hormone therapy in lupus erythematosus disseminatus . J Lab Clin Med 1961; 37: 698-702 .

25.

Schur PH , Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus . N Engl J Med 1968; 278: 533-538 .

26.

Lloyd W , Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE) . Medicine (Baltimore) 1981; 60: 208-217 .

27.

Houssiau FA , D’Cruz D , Vianna J , Hughes GR. Lupus nephritis: the significance of serological tests at the time of biopsy . Clin Exp Rheumatol 1991; 9: 345-349 .

28.

Schur PH. Complement and systemic lupus erythematosus. In Wallace DJ , Hahn BH eds. Dubois’ lupus erythematosus. Baltimore: Williams and Wilkins , 1993, 245-262.

29.

Garcia-Carrasco M , Ramos-Casals M , Cervera R et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients . Semin Arthritis Rheum 2001; 30: 366-373 .

30.

Swaak AJ , Groenwold J , Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus . Ann Rheum Dis 1986; 45: 359-366 .

31.

ter Borg EJ , Horst G , Hummel EJ , Limburg PC , Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study . Arthritis Rheum 1990; 33: 634-643

32.

Petri M , Genovese M , Engle E , Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study . Arthritis Rheum 1991; 34: 937-944 .

33.

Esdaile JM , Abrahamowicz M , Joseph L , MacKenzie T , Li Y , Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail . Arthritis Rheum 1996; 39: 370-378 .

34.

Walz LeBlanc BA , Gladman DD , Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares . J Rheumatol 1994; 21: 2239-2241 .

35.

Holers VM , Girardi G , Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss . J Exp Med 2002; 195: 211-220 .

36.

Blanco Y , Ramos-Casals M , Garcia-Carrasco M , Cervera R , Font J , Ingelmo M. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: a report of 3 new cases and a review of the literature . Rev Clin Esp 1999; 199: 586-588 .

37.

Weber M , Hayem G , De Bandt M et al. Classification of an intermediate group of patients with antiphospholipid syndrome and lupus-like disease: primary or secondary antiphospholipid syndrome ? J Rheumatol 1999; 26: 2131-2136 .

38.

Font J , Cervera R. For debate: 1982 revised criteria for classification of systemic lupus erythematosus. Ten years later . Lupus 1993; 2: 339-341 .